NCT04335721 is a Phase 1, PHASE2 clinical trial of Voxelotor in Sickle Cell Disease, sponsored by University of Illinois at Chicago.

Who is sponsoring NCT04335721?

NCT04335721 is sponsored by University of Illinois at Chicago.

What drugs are being tested in NCT04335721?

Interventions in NCT04335721: Voxelotor.

What condition does NCT04335721 study?

NCT04335721 studies Sickle Cell Disease, Sickle Cell Nephropathy.

Is NCT04335721 still recruiting?

NCT04335721 is currently terminated. Last updated 3 April 2025.

Last reviewed 2025-04-03 · How we verify

NCT04335721

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease

Terminated Phase 1, PHASE2 Last updated 3 April 2025

What this trial tests

Phase 1, PHASE2 trial testing Voxelotor in Sickle Cell Disease in 12 participants. Terminated before completion.

Timeline

16 March 2021

Primary endpoint
7 October 2024

7 October 2024

Quick facts

Lead sponsor	University of Illinois at Chicago
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	16 March 2021
Primary completion	7 October 2024
Estimated completion	7 October 2024
Sites	1 location across United States

Drugs / interventions tested

Voxelotor (voxelotor) — full drug profile →

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sickle Cell Nephropathy — all drugs for Sickle Cell Nephropathy →

Sponsor

University of Illinois at Chicago

Who can join

18 and older, any sex, with Sickle Cell Disease or Sickle Cell Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD progression (presence of both hemoglobinuria and urine albumin concentration ≥ 30 mg/g creatinin

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.
Piel FB, Rees DC, DeBaun MR, Nnodu O, et al · · 2023 · cited 100× · PMID 37451304 · DOI 10.1016/s2352-3026(23)00096-0
The nephropathy of sickle cell trait and sickle cell disease.
Ataga KI, Saraf SL, Derebail VK. · · 2022 · cited 63× · PMID 35190716 · DOI 10.1038/s41581-022-00540-9
Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials.
Ali MA, Ahmad A, Chaudry H, Aiman W, et al · · 2020 · cited 41× · PMID 32841705 · DOI 10.1016/j.exphem.2020.08.008
Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome.
Ogu UO, Badamosi NU, Camacho PE, Freire AX, et al · · 2021 · cited 23× · PMID 33658881 · DOI 10.2147/jbm.s291394
Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.
Barak M, Hu C, Matthews A, Fortenberry YM. · · 2024 · cited 14× · PMID 38786070 · DOI 10.3390/cells13100848
Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB, Carpenter A, Dale-Harris I, Dorée C, et al · · 2023 · cited 7× · PMID 37539955 · DOI 10.1002/14651858.cd012380.pub3
Using disease-modifying therapies in sickle cell disease.
Rai P, Ataga KI. · · 2023 · cited 4× · PMID 38066905 · DOI 10.1182/hematology.2023000485
Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations.
Obadina M, Obadina M, Wilson S, Derebail VK, et al · · 2023 · cited 2× · PMID 37254256 · DOI 10.34067/kid.0000000000000162

Verify or expand the search:

Other trials of Voxelotor

Trials testing the same drug.

NCT06023199 — Assessing Physical Function in Sickle Cell Patients Taking Voxelotor · Phase 2 · active not recruiting
NCT05981365 — Voxelotor CYP and Transporter Cocktail Interaction Study · Phase 1 · completed
NCT05289570 — Voxelotor for Improving Oxygen Saturation in Adults · Phase 2 · terminated
NCT05018728 — The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia · Phase 2 · terminated
NCT04400487 — Actigraphy Improvement With Voxelotor (ActIVe) Study · Phase 4 · completed

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other University of Illinois at Chicago trials

Trials by the same sponsor.

NCT07498322 — Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System · NA · not yet recruiting
NCT07387705 — On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial · Phase 1 · not yet recruiting
NCT07504120 — The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis · NA · not yet recruiting
NCT07160582 — Cognitive-Motor Training for AD/ADRD Prevention · NA · not yet recruiting
NCT07498348 — Apple Watch Evaluation of Endodontics Occupational Stress · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04335721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Chicago
Last refreshed: 3 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04335721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing